EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.
EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.
EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.
ESC 2022 Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.
ESC 2022 The DELIVER trial shows that dapagliflozin reduced the risk of CV death or worsening HF in patients with HFmrEF or HFpEF, with no attenuation of treatment benefit in patients with the highest EF.
ESC 2022 A pooled analysis of DAPA-HF and DELIVER was undertaken to examine the effect of dapagliflozin in patient with heart failure across the entire spectrum of ejection fraction.
Two meta-analyses were performed including SGLT2i trials in HF patients: one including DELIVER and EMPEROR-Preserved and the other one of the 5 trials DELIVER, EMPEROR-Preserved, DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF.
ESC 2022 After the DELIVER trial was unblinded, two meta-analyses were performed of large SGLT2i trials in patients with HF. What are the findings and implications of these 2 meta-analyses?
ESC 2022 Prof. Jhund talks about the findings and implications from a pooled analysis of DAPA-HF and DELIVER with dapagliflozin in HF patients covering the entire LVEF spectrum.
In this program, three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.
The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.
Watch a discussion by three experts on initiating SGLT2i in HFrEF.